Get the Stockscreener App
8.54
0.47%
0.04
After Hours:
8.55
0.01
+0.12%
Agenus Inc stock is traded at $8.54, with a volume of 672.25K.
It is up +0.47% in the last 24 hours and up +2.15% over the past month.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
See More
Previous Close:
$8.50
Open:
$8.57
24h Volume:
672.25K
Relative Volume:
0.16
Market Cap:
$385.68M
Revenue:
$123.87M
Net Income/Loss:
$62.49M
P/E Ratio:
5.1153
EPS:
1.6695
Net Cash Flow:
$-87.53M
1W Performance:
+8.79%
1M Performance:
+2.15%
6M Performance:
+139.89%
1Y Performance:
+118.97%
1-Day Range:
$8.40
$8.68
1-Week Range:
$7.60
$8.82
52-Week Range:
$2.71
$8.85
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
8.54 | 385.68M | 123.87M | 62.49M | -87.53M | 1.6695 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last? - Eastern Progress
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Dura - The National Law Review
Agenus (AGEN) Stock Jumps 8.73% to $7.85, Pressing Toward Key ResistanceStock Buy Zone - dars.gov.et
Agenus Stock Price Forecast. Should You Buy AGEN? - StockInvest.us
Agenus Initiated at Buy by Chardan Capital - Moomoo
Agenus Inc (AGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
New Agenus (AGEN) director receives 7,500 stock options - Stock Titan
Spouse-held shares feature in Agenus (AGEN) director's stake - Stock Titan
September Stakeholder Webcast on ROBBIN Phase 3 and Neoadjuvant ImmunotherapyAgenus - Oncodaily
Agenus Inc Share PriceAGEN, RNS News, Articles, Quotes, & Charts (NASDAQ:AGEN) - Proactive financial news
AGEN S-3 FilingsAgenus Inc. SEC S-3 - stocktitan.net
Agenus Inc. (AGEN) Shareholder/Analyst CallSlideshow (NASDAQ:AGEN) 2026-09-11 - Seeking Alpha
BOT+BAL: Three-Year Overall Survival Data in Recurrent Ovarian Cancer – Agenus - Oncodaily
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - BioSpace
Agenus to Present 3-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - oncodaily.com
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Agenus Company Profile & Introduction - moomoo.com
Agenus to Participate in Upcoming September Investor Conferences - Business Wire
Immigrant Entrepreneur Garo H. Armen Of Agenus Inc. Riccardo Braschi (I0EURkuuPl) - Mshale
New Phase 2 NEST Results Support Neoadjuvant BOT+BAL in Colon Cancer – Agenus - Oncodaily
Agenus reports survival data for colorectal cancer treatment By Investing.com - Investing.com South Africa
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism - Yahoo Finance
Agenus reports survival data for colorectal cancer treatment - Investing.com
Agenus Inc: Shareholders Revolt Over Executive Pay! My Thoughts. Tampa Bay Rays (VzxHMd1TNP) - Mshale
Agenus Inc.AGEN Stock Chart Technical Analysis For 09-21-2020 Sporting Cp (0os72ROBex) - Mshale
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer - Yahoo Finance
🔴 Agenus Inc. AGEN Stock Trading Facts 🔴 Gianna Nannini (9cYwfB9Crl) - Mshale
Agenus | Learn How I Turned $15,253 Into $1,613,442 Trading Biotech Stocks Donald Gibb (Gf1su3sDdD) - Mshale
AGEN Stock Analysis | Agenus Inc Stock Update & Chart Breakdown Traffic Stop (vDz5v0ltyg) - Mshale
Bold Move By Agenus: Cutting Costs By 60% To Focus On Groundbreaking Cancer Treatments Nikoloz Basilashvili (41VwNJliWR) - Mshale
A.G.E.N.U.S. 8-K: My Take On The C.F.I.U.S. Delay Ctv News Ottawa (HFy9tZJhiU) - Mshale
Why Agenus (AGEN Stock) Just Rocketed Up—Buy Now Or Too Late? Cigarette (l3DDhgoK4D) - Mshale
Insider Trading AGEN Agenus Inc 2021 05 18 Blowing Dust Advisory (aETsN3n1J0) - Mshale
Agenus Inc AGEN CEO Garo Armen On Q4 2019 Results David Muir (NjcFXnx049) - Mshale
Agenus (AGEN) Chart: Ends Down by 5.19% at $7.67 in Latest Trading; Current Setup: $7.29 and $8.05 Define the Nearby Reference Levels in the Available RecordDescending Triangle - careplusvn.com
Agenus Inc (AGEN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
AGEN Stock TUESDAY MADNESS! (news Update) Agenus Stock Analysis Best Broker Review Challenge Cup Final 2026 (5MyfQl06Kh) - Mshale
Agenus Inc. (AGEN) Latest Stock News & Headlines - Yahoo Finance
Agenus extends $24.75 million loan maturity, adjusts payment terms with Ocean 1181 - Investing.com
Form 8K Agenus Inc For: 18 August By Investing.com - Investing.com South Africa
Agenus Extends $24.75M Term Loan to 2029 at 13% With Ocean 1181; Partly Payable in Stock - TradingView
Agenus (NASDAQ: AGEN) to pay part of 13% loan interest in stock - Stock Titan
Agenus Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
AGEN Q2 2026 Earnings: EPS Misses Estimates by 119.61% as Shares Slide 2.32%EBITDA Estimate Trend - Vinanet
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):